Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Qiu, Miao-Zhen; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Cruz Correa, Marcia; V Zimina, Anastasia; Bai, Yuxian; Shi, Jianhua; Lee, Keun-Wook; Wang, Jufeng; Poddubskaya, Elena; Pan, Hongming; Young Rha, Sun; Zhang, Ruixing; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Chao, Yee; Wyrwicz, Lucjan; Disel, Umut; Pazo Cid, Roberto; Fornaro, Lorenzo; Evesque, Ludovic; Wang, Hongwei; Xu, Yaling; Li, Jiang; Sheng, Tao; Yang, Silu; Li, Liyun; Moehler, Markus; Xu, Rui-Hua

doi:10.1136/bmj-2023-078876

Public

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Shared by NobleBlocks on May 28, 2024 • 12:00 AM UTC

Authors:

Miao-Zhen Qiu

Do-Youn Oh

Ken Kato

Abstract

Abstract Objective To evaluate the efficacy and safety of tislelizumab added to chemotherapy as first line (primary) treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma compared with placebo plus chemotherapy. Design Randomised, double blind, placebo controlled, phase 3 stud...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!